Antidepressant Side Effects: What Do SSRIs and SNRIs Cause?

What Are the Most Common Antidepressant Side Effects With SSRIs and SNRIs?

The most common antidepressant side effects with SSRIs and SNRIs are sexual problems, emotional blunting, weight gain, sleep changes, sweating, nausea and tiredness. Some fade within weeks, while others last as long as the drug is taken. A separate set of symptoms can appear when the dose is lowered.

Picture someone who started Lexapro (escitalopram) in their twenties, after a hard year at college. After 15 years they feel steady, but they notice they rarely cry, rarely laugh hard, and sex feels muted. Is that the medication, the passing of time, or both? This guide covers what these drugs commonly do to the body and mind, how side effects can change over years, and why the picture changes again once the dose starts coming down.

How Many People Take These Medications, and for How Long

These drugs are among the most widely used medicines in the country. About 1 in 6 US adults (16.6%) reported currently taking an antidepressant in a 2025 national survey of more than 30,000 adults (Perlis et al., 2026). That survey used a weighted online panel.

Many people take them for a long time. Among Americans taking these medications in 2011-2014, 68% had been taking them for two years or more, and about one-quarter for 10 years or more (Pratt et al., 2017). Those figures are more than a decade old, but they are the newest official US numbers on duration.

This matters for side effects. The Maudsley Deprescribing Guidelines point out that there are no long-term placebo-controlled trials designed to measure the long-term health effects of these drugs, so most of what we know about years of use comes from observational studies, with all the confounding those studies carry (Horowitz & Taylor, 2024). The side effects listed on a label mostly reflect short exposure. Someone on year 12 is living in territory the trials did not measure.

What SSRIs and SNRIs Do in the Brain

SSRIs bind to the serotonin transporter, the protein that clears serotonin from the space between nerve cells, and block it. SNRIs do the same and also block the transporter for noradrenaline. Brain-imaging work shows that SSRIs occupy roughly 80% of serotonin transporters at their minimum therapeutic doses, and that occupancy rises steeply at low doses and then plateaus at higher doses (Meyer et al., 2004).

The brain does not sit still while this happens. Over weeks and months it adapts to the drug's presence, changing how its own signaling works to keep things in balance. That adaptation helps explain two things people often notice: some effects that build up over years of use, and the symptoms that can appear when the dose drops and the brain has to adjust to the absence of the medication.

One thing worth saying plainly: the idea that depression is caused by a chemical imbalance has never been proven. These drugs act on transporters and receptors in measurable ways, and that is what the rest of this guide builds on.

Side Effects People Commonly Report

Side effects vary a great deal from person to person, by drug, and by dose. The Maudsley Deprescribing Guidelines list sleepiness, dry mouth, heavy sweating, sexual dysfunction, weight gain, dizziness and nausea among the effects patients most often attribute to their medication (Horowitz & Taylor, 2024).

Sexual Side Effects

Sexual problems are among the most reported effects of SSRIs and SNRIs: lower desire, reduced genital sensation, and delayed or absent orgasm in people of any sex. A meta-analysis found treatment-emergent sexual dysfunction was common across many of these drugs, with rates differing between them (Serretti & Chiesa, 2009). In a minority of people, sexual effects persist after the drug is stopped, a condition called post-SSRI sexual dysfunction, or PSSD (Reisman, 2020). For how this plays out with Cymbalta (duloxetine), see our guide to Cymbalta sexual side effects.

Emotional Blunting

Many people describe feeling flat: fewer lows, but fewer highs too. In a survey of patients with depression, emotional blunting was a commonly reported experience across these medications (Goodwin et al., 2017). It is not only the underlying distress. A placebo-controlled study in healthy volunteers who took escitalopram for several weeks found changes in how people responded to reward and feedback, consistent with blunting caused by the drug itself (Langley et al., 2023). For some people that flatness feels protective. For others it strains relationships and makes life feel muted.

Weight and Other Body Changes

Weight gain is one of the most common reasons people question their medication. The Maudsley Deprescribing Guidelines note that long-term use may cause more weight gain than short-term trials suggest (Horowitz & Taylor, 2024). A 2025 network meta-analysis in The Lancet found that individual drugs differ in their effects on weight, heart rate and blood pressure, so the drug matters, not just the class (Pillinger et al., 2025).

Sleep, Sweating, Stomach and Energy

Daytime sleepiness, insomnia, vivid dreams, night sweats, nausea, diarrhea or constipation, and fatigue are all commonly reported. Some of these settle in the first weeks; others persist. Some show up differently in women, which we look at in Zoloft side effects in women.

Less Common Risks Worth Knowing

SSRIs and SNRIs reduce the serotonin stored in platelets, which affects clotting and raises the risk of bleeding, especially alongside other drugs that affect bleeding (Horowitz & Taylor, 2024). Low blood sodium is another recognized risk, particularly in older adults. Large observational studies have also linked long-term use with cardiovascular outcomes (Bansal et al., 2022). This does not establish causation, because people prescribed these drugs differ from people who are not, but it is consistent with a real signal that deserves a conversation with your clinician.

How Side Effects Can Change Over Years of Use

The side effects of month three are not always the side effects of year ten. In a qualitative study of people on these medications long term, many described real benefits alongside adverse effects they had come to live with, and some were unsure whether the drug was still doing what it once did (Cartwright et al., 2016). The Maudsley Deprescribing Guidelines describe a naturalistic study in which the risk of reporting side effects rose with each year of use (Horowitz & Taylor, 2024).

The person who started a medication at 22, during a crisis, is not the person reviewing it at 40. Priorities shift: a relationship, a pregnancy, a career, a wish to feel more fully. What felt like a fair trade then may feel different now, and what you are feeling about it is real. We look at this in more depth in our guide to the long-term effects of SSRIs.

Side Effect or Withdrawal? Telling Them Apart

Once the dose starts coming down, a new set of symptoms can appear, and they are easy to confuse with side effects or with the original distress. NICE's 2022 guideline notes that symptoms after stopping or lowering a dose can include sensations not typical of depression, such as dizziness or electric-shock feelings, and can include low mood, anxiety and tearfulness (NICE, 2022).

The mood row is where people most often get misread. Low mood after a dose change is often taken as proof that you "need" the drug, when it may be the brain adjusting to the absence of the medication. When the question of relapse does come up, it helps to know that most people recover from depression within a year, including those with severe episodes (Whiteford et al., 2013).

How Common Are Symptoms When the Dose Comes Down?

A 2019 systematic review found that across 14 studies, an average of 56% of people who stopped these medications experienced withdrawal effects, with a range of 27% to 86% (Davies & Read, 2019). The review mixed study designs, including online surveys, and its estimate has been publicly debated.

In a 2025 survey of 310 NHS primary-care patients in England who had tried to stop, 79% reported withdrawal symptoms, 45% rated them moderately severe or severe, 20% had symptoms lasting more than three months and 10% for more than a year (Horowitz et al., 2025). People who had taken the drug for more than two years before stopping were far more likely to have a difficult time than those who had taken it for under six months. Dr. Mark Horowitz, its lead author, is Outro Health's clinical co-founder.

How long these symptoms last is highly individual. Some people have mild symptoms for days or weeks, while many have prolonged symptoms that are often mistaken for relapse. Risk factors include longer time on the drug, a higher dose, a short half-life, past difficulty stopping, and stopping quickly. A short half-life shapes how fast symptoms arrive, but the drug clearing the body does not mean the brain's adaptations have reversed, so prolonged symptoms remain possible. NICE (2022) advises that relapse does not usually happen as soon as someone stops or lowers an antidepressant, but timing alone cannot settle the question, because withdrawal does not always start right away.

Delayed Onset Withdrawal: When Symptoms Arrive Weeks Later

Withdrawal symptoms can be delayed for several weeks or even months after a dose reduction or the last dose, often called delayed onset withdrawal. It is best known with Prozac (fluoxetine), because its active metabolite, norfluoxetine, stays in the body for weeks, so symptoms can surface late. It also happens with shorter-acting SSRIs and SNRIs (Horowitz & Taylor, 2022). One hypothesis in the Maudsley Deprescribing Guidelines is that drug effects in the brain fall more slowly than drug levels in the blood, so serotonin transporter occupancy lags behind (Horowitz & Taylor, 2024).

This matters because symptoms that appear weeks after a change often get read as relapse or as a new illness, not as withdrawal (Fava et al., 2015; Davies & Read, 2019). It also shapes pacing. Horowitz and Taylor (2019) suggest waiting about four weeks after an SSRI reduction to watch for late effects, and the Maudsley Deprescribing Guidelines suggest six-to-eight-week gaps between some fluoxetine reductions for the same reason. A 2023 review found that longer use and past withdrawal experience are associated with a higher risk of withdrawal, though the authors describe that evidence as limited (Horowitz et al., 2023). If something feels off a month after a change, it is worth raising with your clinician before assuming relapse.

Why Small, Gradual Reductions Follow From the Pharmacology

Go back to the occupancy curve. Because each milligram has a larger effect on the serotonin transporter at low doses than at high doses, cutting a dose by equal milligram amounts makes the later cuts far bigger in their effect on the brain. Reducing doses hyperbolically, by progressively smaller amounts, lowers the drug's effect in roughly even steps (Horowitz & Taylor, 2019). This is the basis of hyperbolic tapering. It rests on pharmacology and observational experience rather than a randomized trial.

NICE (2022) describes the same shape: reductions where each dose is a proportion of the previous one, with smaller reductions and liquid formulations as the dose gets lower. In general terms, a clinician-guided plan tends to look like this:

1. A clinician estimates how likely someone is to have trouble coming off, based on factors like time on the drug and past experience.
2. Each reduction is a fraction of the current dose, not a fixed number of milligrams. Peer-led communities found reductions of about 10% of the most recent dose helpful, which the Maudsley Deprescribing Guidelines note closely approximates hyperbolic schedules.
3. The next step waits until symptoms from the last one have largely settled, so the pace follows how you feel, not a fixed calendar.
4. Final doses are often far smaller than the lowest tablet, reached with liquids or compounded doses, so the last step to zero is no bigger in effect than the steps before it.

These numbers are illustrative. A prescribing clinician individualizes every plan, final dose included, and any change is a shared decision with them. Please do not stop an antidepressant suddenly without clinical support.

Who This Guide Is for, and Who It Is Not For

• For you if you have been on an SSRI or SNRI for a while and want to understand the side effects you live with.
• For you if you are weighing, with your clinician, whether your current medication still fits your life.
• For you if you have tried lowering your dose before and felt unwell, and want to understand why.
• Not for you if you are looking for guidance on starting or choosing a medication; this guide does not cover that.
• Not for you as a replacement for a clinician; it cannot give you a personal dose plan.
• Not for you if you are in crisis right now; please contact 988 or local emergency services.

Conclusion

Side effects from SSRIs and SNRIs are common and varied: sexual changes, emotional flatness, weight gain, sleep and sweating problems, and less common risks like bleeding. Many people live with them for years, and the trade-off can look different later in life than it did at the start. If you and your clinician decide to lower the dose, a second set of symptoms can appear, sometimes weeks or months later, often mistaken for relapse, and more likely after longer use. The most defensible reading of the evidence is that the brain's adaptation to these drugs is real, that it takes time to unwind, and that reductions sized to the hyperbolic occupancy curve are the approach that best matches the pharmacology.

How Outro Health Supports a Gradual Taper

If side effects have you thinking about coming off, and you would like support doing it, Outro Health is a telehealth clinic built for that. After an evaluation, the Taper Management Program pairs you with a dedicated clinician trained in hyperbolic tapering, with regular visits, messaging between appointments, symptom tracking, and compounded small doses when the plan needs them. Outro Health clinicians are trained to recognize withdrawal, including symptoms that show up late, and not confuse it with relapse. If your body needs to slow down, the taper slows down. Outro Health's tapering program is currently available to patients in more than a dozen states, including California, Florida, New York, Texas and more. You don't need to have it all figured out to find out whether an evaluation fits.